This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

POSTER
Vibrance-2: Study Design and Methods for a Phase 2, Randomised, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Narcolepsy Type 2
Author(s):

David Plante,1 Ron Grunstein,2 Giuseppe Plazzi,3 Chad Ruoff,4 Jandira Ramos,5 Shifang Liu,5 Sergey Yagoda,5 Bhaskar Rege5

1University of Wisconsin School of Medicine and Public Health, UW Department of Psychiatry, Madison, WI, USA; 2Woolcock Institute of Medical Research, Macquarie Park, Sydney, Australia; 3IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; 4Mayo Clinic Hospital, Division of Pulmonary Medicine, Phoenix, AZ, USA; 5Alkermes, Inc., Waltham, MA, USA

Content available until 09/27/2026